Eisai Launches Leqembi in India for Early Alzheimer’s Disease
The Story: Eisai has launched Leqembi (lecanemab) in India after CDSCO approval, introducing the country’s first disease-modifying treatment for early Alzheimer’s disease.
The Take: The launch marks a major step forward for Alzheimer’s care in India and positions Eisai at the forefront of a fast-growing but underserved market.
Creador in Talks to Acquire 10% Stake in Leeford Healthcare
The Story: Creador is nearing a deal to acquire a 10% stake in Leeford Healthcare for around ₹800 crore, valuing the company at up to ₹8,500 crore.
The Take: The investment reinforces growing investor confidence in Indian pharma and reflects sustained interest in profitable, export-focused healthcare businesses.
Piramal Pharma Solutions Expands Peptide Manufacturing
The Story: Piramal Pharma Solutions has launched a new spray drying suite at its Turbhe facility to support peptide and complex molecule development.
The Take: The expansion strengthens Piramal’s capabilities in high-potency peptides and positions it to capture growing demand for advanced CDMO services.
Aurobindo Pharma to Merge Eugia Pharma
The Story: Aurobindo Pharma has approved the merger of its wholly owned subsidiary Eugia Pharma Specialities with the parent company to streamline operations.
The Take: The move could improve efficiency across Aurobindo’s oncology and injectables business while strengthening synergies across manufacturing, R&D, and commercialization.
The Story: Fermenta Biotech has listed its shares on the NSE under FERMENTA, adding to its existing BSE listing.
The Take: The dual listing could improve liquidity, expand investor access, and strengthen Fermenta’s capital market presence as it grows its Vitamin D3 and nutrition business.
Gland Pharma, Neuland Partner on Sterile APIs
The Story: Gland Pharma and Neuland Laboratories have entered a strategic CDMO partnership to expand sterile API manufacturing at Gland’s Visakhapatnam facility.
The Take: The partnership strengthens both companies’ capabilities in complex injectable therapies and positions them to capture growing global demand for sterile API CDMO services.
